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Letters to the Editor
Is Prolong Use of Statins
Associated With Increase
in the Risk of Diabetes?
The study by Wang et al. (1) assessed the risk of diabetes
associated with statin use in the general population. The authors
concluded that statin therapy is associated with an elevated risk for
diabetes. However, the study does not indicate the classes or
proportion of the different antihypertensive drugs (AHDs) admin-
istered in the statin-treated and control populations. This infor-
mation is imperative because thiazide diuretics and specific beta-
blockers exhibit undesirable glycemic effects.
Assessment of the ALLHAT study (Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial) re-
vealed that the 4-year incidence of new-onset diabetes mellitus was
significantly elevated in the chlorthalidone group compared with
either the amlodipine or lisinopril group (11.6% vs. 9.8% and 8.1%,
respectively; p  0.05) (2). Comparable outcomes were also
obtained from the INSIGHT (International Nifedipine GITS
Study of Intervention as a Goal in Hypertension Treatment) and
ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial–
Blood Pressure Lowering Arm) trials (3,4). These effects of diuretic
AHDs on glucose metabolism are plausibly due to hypokalemia
induced by these drugs.
Hyperglycemia induced by beta-blockers is due to the reduction
in peripheral blood flow, followed by the channeling of blood away
from locales of glucose uptake, thereby reducing glucose clearance.
A systematic review by Elliott and Meyer (5), with 48 randomized
groups of 22 clinical trials involving 143,153 participants, revealed
that association of AHDs with incident diabetes is the highest for
beta-blockers and diuretics (in rank order).
Therefore, the question that remains unrequited in the current
study – “Is the adverse glycemic effect of statins observed in the
present study getting augmented, as a greater number of subjects in
the statin-group are being treated for hypertension with diuretics
or beta-blockers?”
Furthermore, a prospective population-based cohort study by
Dunder et al. (6) examined the impact of blood glucose elevationon the risk of developing myocardial infarction in individuals
between 50 and 60 years of age who were receiving AHDs. They
found that the elevated blood glucose and proinsulin levels
produced by use of diuretics and beta-blockers were linked to the
increased risk of myocardial infarction in these subjects. Therefore,
in the current study, if the statin-treated group has a higher
number of subjects receiving diuretics and beta-blockers, then the
favorable outcome of statins may be further augmented.
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Reply
We thank Dr. Banerjee for his comments regarding our publica-
tion on statin therapy and the risk of incident diabetes (1). He
highlighted for us the importance of diabetogenic effects of
concomitant medications, particularly diuretics and beta-blockers,
which have been independently associated with a higher risk of
diabetes (2,3).
The effects of diuretics and beta-blockers were essential in our
analysis because 73.9% of subjects in our population had hyper-
tension and 8.6% had heart failure. Our approach of matching
measurable comorbid risks to establish the study cohort resulted in
a similar distribution of demographic characteristics and cardio-
vascular comorbidities. There was no significant difference in the
proportions of diuretic and beta-blocker use among the control
group and the statin group (13.1% vs. 13.0%, p  0.795 [diuret-
ics]; 34.5% vs. 34.3%, p  0.693 [beta-blockers]). Statins, diuret-
ics, and beta-blockers were associated with an increase in risk of
incident diabetes; hazard ratios (95% confidence intervals) were
